All articles by Frankie Fattorini

Frankie Fattorini

Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.

Patient burden as an operational metric of clinical trial success

Patient burden should join standard operational metrics like cost, timelines, and regulatory compliance to ensure long-term clinical trial success, argues…
Collaboration with partners drives successful clinical trials, says Bayer exec

Closer relationships with clinical trial partners are key to ensuring long-term trial success with German pharma giant Bayer, says the…
AI to become as foundational as the internet in clinical trials, experts say

Artificial intelligence (AI) is expected to not only supplement clinical trials, but redefine the sector, while the industry braces for…
CTSWC25: The future of clinical trial supply hinges on risk management

Regulatory overhaul, international trade tariffs, and the burgeoning disruption imposed by artificial intelligence (AI) are moving the clinical trials industry…
Clinical trial supply chains in the US navigate pharma tariffs

Tariffs imposed by President Trump on US pharma imports have left experts charting a new course for the nation’s clinical…

Adapting to funding and operational hurdles in today’s clinical trials landscape

Against the backdrop of geopolitical tensions and economic measures such as tariffs, which are influencing supply chains across numerous industries,…
AI could personalise clinical trial consent, but privacy concerns remain

Artificial intelligence (AI) is revolutionising clinical trials, offering ways to improve the consent process, but concerns regarding the complete reliability…
Clinician capacity remains a major bottleneck in UK’s push for cancer trials

While encouraged by revised regulations aimed at boosting UK clinical studies, experts say busy schedules of NHS workers present a…
ASCO25: Kura’s Phase II ziftomenib results trigger NDA acceptance from FDA

A November 2025 PDUFA date has been set for Kura Oncology’s oral acute myeloid leukaemia (AML) drug ziftomenib following the…
ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia

Amgen’s Nplate (romiplostim) has demonstrated efficacy in treating thrombocytopaenia among gastrointestinal (GI) cancer patients, as Phase III RECITE results are…